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INTRODUCTION
Cortisol is an important component of the stress re-
sponse. It has critical roles in the maintenance of nor-
mal functions in the immune system, vascular tone, car-
diac output, metabolic states, and several other cellular 
processes (1,2). The prevalence of adrenal insufficiency 
(AI) has been reported to be 66% in decompensated 
cirrhosis, 33% in acute liver failure, 72% in patients in 
transplantation centers, 51% in cirrhotic patients with 
sepsis, 68–77% in cirrhotic patients with septic shock, 
and 38% in stable cirrhotic patients without any hemo-
dynamic instability (1,3-7).
In clinical practice, AI is diagnosed based on basal or 
post-adrenocorticotrophic hormone (ACTH) stimulation 
levels of serum total cortisol (TC). More than 90% of cor-
tisol in the serum is bound to cortisol-binding globulin 
(CBG) or albumin. Because the serum concentrations of 
these proteins are reduced in liver cirrhosis, the measure-
ment of the level of free cortisol (FC), which is the biolog-
ically active fraction, may be a more reliable parameter 
for the diagnosis of AI in cirrhotic patients (8,9).
With basal and stimulated TC levels, AI has been report-
ed to be diagnosed in 40% of severely ill hypoprotein-
emia ill. However, the basal and ACTH-stimulated FC 
levels of these patients remained within normal ranges 
(10). The measurement of the level of FC is technically 
difficult and expensive and is not routinely used (11). 
The level of FC can be calculated using the levels of TC 
and CBG (12). Salivary cortisol (SC) measurement has 
been suggested as an alternative method in the diag-
nosis of AI. It correlates well with FC and is not affected 
by serum protein levels (12-15). In hemodynamically 
stable cirrhotic patients, the prevalence of AI has been 
reported to be 33% with TC measurements. However, 
according to SC, only 9.1% of these patients were diag-
nosed with AI (16).
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ABSTRACT
Background/Aims: Reports on adrenal insufficiency (AI) are unexpectedly high in cirrhosis, and the diagnosis 
of this condition remains a challenge. We aimed to define the prevalence rate of AI in stable cirrhotic patients 
and determine the correlations of free cortisol and salivary cortisol with total cortisol.
Materials and Methods: Between January 2011 and September 2011, 110 consecutive cirrhotic patients with-
out any infection or hemodynamic instability were enrolled. Baseline total and salivary cortisol levels were 
measured. The free cortisol level was calculated according to the Coolens’ formula. Post-stimulation total and 
salivary cortisol levels were measured, and the free cortisol level was recalculated.
Results: The mean age of the patients was 62.1±11.4 years. There were 54 males (49.1%). The mean Child-
Turcotte-Pugh (CTP) score was 7.2±2.3. Twenty-two (20%) patients were at the CTP-C level. AI was present in 23 
(20.9%) and 17 (15.5%) of all patients according to the total and free cortisol criteria, respectively. For basal and 
stimulated levels, salivary cortisol rather than total cortisol correlates well with free cortisol.
Conclusion: The diagnosis of AI on the basis of total cortisol measurement overestimates the prevalence of AI 
in cirrhosis. Salivary cortisol, which correlates well with free cortisol, is a promising alternative for the diagnosis 
of AI in cirrhotic patients. 
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The aims of this study were to define the prevalence rate of AI 
in stable cirrhotic patients and to determine the correlations of 
FC and SC with TC.
MATERIALS AND METHODS
Study design
This prospective observational study was conducted at Başkent 
University Adana Training and Research Center between Janu-
ary 2011 and September 2011. The study included 110 stable 
cirrhotic patients admitted to the outpatient clinic. The diagno-
sis of cirrhosis was based on biopsy and/or clinical, radiologic, 
and laboratory findings. The exclusion criteria were as follows: 
age<18 years; pregnancy; history of pituitary or adrenal dis-
ease; active infection or sepsis; hemodynamic instability due 
to septic shock or bleeding; administration of albumin, fresh 
frozen plasma, vasopressors, or glypressin; treatment with ste-
roids or other drugs known to influence cortisol secretion (e.g., 
etomidate, ketoconazole) or CBG level; treatment with drugs 
known to affect saliva secretion; active intake of alcohol; and 
diagnosis of Sjogren’s disease and hepatocellular carcinoma. 
Written informed consent was obtained from all patients. The 
study protocol was approved by the ethical committee of 
Başkent University (KA10/154). 
Study protocol
On the first day, a physical examination of each patient was 
performed. Blood and saliva samples were taken 15 min after 
the insertion of an indwelling intravenous catheter. Particular 
attention was paid to the absence of blood in the mouth. Sixty 
minutes after the intramuscular administration of 250 µg cor-
ticotrophin (Syancten, Novartis Pharma SAS; Rueil-Malmaison, 
France), blood and saliva were sampled again. The patients 
were not allowed to smoke, brush their teeth, eat, or drink 
anything for 1 h before sampling. Basal and stimulated saliva 
samples were collected with cotton-wrapped standard sterile 
sticks that were kept in the mouth for 3 min. After sampling, 
the saliva-imbued cotton tip was collected in a plastic tube in 
a standard manner according to the supplier’s instructions and 
was maintained at −20 °C until analysis. 
Biochemical assessments, including complete blood count, 
prothrombin time, and total protein, albumin, bilirubin, serum 
TC, and CBG measurements, were performed using the basal 
blood samples. TC level was measured again 60 min after stim-
ulation. 
Biological assays
The severity of liver disease was assessed with the Child-
Turcotte-Pugh (CTP) and Model for End-stage Liver Disease 
(MELD) scoring systems. Serum total protein, albumin, liver 
enzyme, and bilirubin levels were measured with calorimet-
ric methods using a Roche Modular DP Autoanalyzer (Roche 
Diagnostics, 16 GmBH; Mannheim, Germany). The prothrom-
bin time was measured by a coagulometric assay (Siemens 
Healthcare Diagnostic Products, GmbH). The total serum cor-
tisol level was measured with ECLIA (E170, Roche Diagnostics; 
Switzerland). CBG and SC measurements were performed by a 
radioimmunoassay (CBG-RIA-CT, DIAsource Immunoassays SA; 
Nivelles, Belgium) and ELISA (EUROIMMUN EQ, 6141-9601 S; 
Lübeck, Germany), respectively. The level of FC was calculated 
by Coolens’ formula as follows (12):
Serum free cortisol (FC)=√(z2+0.0122×TSC)−z
z=0.0167+0.182 (CBG−TSC)
Definitions
The diagnosis of AI according to TC was defined as follows: a 
basal level (T0) of less than 5 µg/dL, a level of less than 18 µg/dL 
at 1 h after the injection of corticotrophin (T60), or an increase of 
less than 9 µg/dL from T0 to T60 (∆) (17,18). According to FC, AI 
was defined as a T60 level of less than 33 nmol/L (19-21). 
Statistical methods
Statistical analyses were performed using SPSS 18.0 software 
(SPSS Inc.; Chicago, IL, USA). Parameters were expressed as 
mean±SD or n (%). Continuous variables were compared by 
Student’s t-test. For the comparison of categorical variables, 
the Pearson chi-squared test was used. For comparing vari-
ables of more than two groups, ANOVA was applied. The corre-
lation between continuous variables was assessed with Spear-
man’s correlation test. For Spearman’s coefficient, p<0.05 was 
accepted as significant. 
RESULTS
A total of 110 patients were enrolled. Their mean age was 
62.1±11.4 years. Fifty-four (49.1%) patients were males. The 
etiologies of cirrhosis were hepatitis B, hepatitis C, and crypto-
genic in 26 (24%), 33 (30%), and 33 (30%) patients, respectively. 
In the remaining 18 patients, other etiologic factors, including 
delta virus (n=3), autoimmune hepatitis (n=1), alcohol (n=7), 
primary biliary cirrhosis (n=5), and Budd-Chiari disease (n=2) 
were detected. The mean CTP score was 7.2±2.3. CBG levels 
were significantly different among the CTP groups (p=0.006). 
The demographic, clinical, and biochemical parameters of the 
patients according to their CTP groups are shown in Table 1. 
The mean basal TC levels were similar between the CTP groups 
(p= 0.788). From CTP-A to CTP-C patients, ∆ levels decreased in 
a statistically significant manner (p=0.003). No statistically sig-
nificant difference was observed between the basal, T60, and 
∆ levels of mean FC and SC among the CTP groups (p>0.05) 
(Table 2). With basal and stimulated levels, mean FC and SC, but 
not TC, showed similar changes between the albumin groups 
(≤2.5 g/dL, 2.5–3.5 g/dL, and >3.5 g/dL) (Table 3). 
The mean basal TC level correlated fairly well with the mean basal 
FC and SC levels (p<0.0001, r=0.539, and r=0.502, respectively). 
There was a good correlation between the mean basal FC and 
SC levels (p<0.0001, r=0.706) (Figure 1). Post-stimulation levels of 
FC and SC were also correlated (p<0.0001, r=0.613). In CTP-C pa-
tients, the basal TC level correlated fairly well with the serum FC 
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level (p=0.013, r=0.521), whereas there was a good correlation be-
tween the basal FC and SC levels (r=0.748, p<0.0001). 
For mean TC measurements, basal levels were similar (p>0.05) 
for patients with high (≥12) and low (<12) MELD scores, where-
as the T60 and ∆ levels were significantly low among patients 
with high MELD scores (p=0.025 and p=0.007, respectively). 
The basal, T60, and ∆ levels of SC did not show any statistically 
significant differences between the MELD groups (p>0.05). 
However, the mean basal FC level was lower in the group with 
high MELD scores, and T60 and ∆ levels of FC were similar be-
tween the MELD groups (p>0.05).
According to the TC levels, AI was diagnosed in 23 (20.9%) of 
110 patients. In total, 34.1% (14/41) of the patients with high 
MELD scores and 13% (9/69) of those with low MELD scores 
were diagnosed with AI. This difference was statistically signifi-
cant (p=0.014).
According to the FC measurements, 17 (15.5%) patients were 
diagnosed with AI. Within the group with high MELD scores, a 
significantly higher percentage of patients satisfied the crite-
ria for AI (p=0.044). Patients with high (≥12) MELD scores were 
more likely to have AI. The difference was statistically signifi-
cant (Table 4). Out of 23 patients who were diagnosed with AI 
based on TC levels, 9 had FC levels of less than 33 nmol/L. The 
agreement between these tests for the diagnosis of AI in cir-
rhotic patients was low (kappa=0.331) (Table 5). 
DISCUSSION
AI has been reported to be high among cirrhotic patients. Ac-
cording to the low dose ACTH test results, AI with TC criteria 
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Patients   CTP-A CTP-B CTP-C p*
Total cortisol Basal  12.6±6.03 13.3±7.1 12.2±5.1 .788
(µg/dL)*** T60 29.8±7.7 28.4±9.3 24.6±7.4 .046
 ∆ 17.1±5.5 15.0±5.7 12.3±4.9** .003
Salivary  Basal 1.9±0.27 1.9±0.2 2.0±0.3 .154
cortisol  T60 5.4±0.9 5.5±0.7 5.6±1.2 .863
(ng/mL)***
 ∆ 3.5±0.8 3.5±0.6 3.5±1.0 .981
Free cortisol  Basal 15.3±1.2 15.7±1.4 15.9±1.6 .168
(nmol/L)*** T60 57.8±29.9 49.7±26.0 49.9±21.0 .309
 ∆ 42.4±30.3 33.9±26.4 33.9±21.9 .281
∆: increase from T0 to T60; CTP: Child-Turcotte-Pugh; T60: level at 60 minutes after stimulation
Within-group comparison was performed after Bonferroni correction. 
*p: for comparison within all groups.
**p=0.003 for comparison between A and C.
***Mean±standard deviation
Table 2. Basal and post-stimulation levels of total, free, and salivary cortisol 
according to CTP groups
  Alb>3.5 Alb: 2.8–3.5 Alb<2.8 
  n: 52 n: 33 n: 25 p
Total cortisol (µg/dL)* Basal  13.3±6.0 12.7±7.2 11.5±4.8 .496
 T60   31.3±6.9 27.2±9.2 23.6±7.6 <.0001
 ∆ 18.0±5.6 14.4±50 12.1±4.7 <.0001
Salivary cortisol (ng/mL)* Basal 1.9±0.3 1.9±0.2 2.0±0.3 .681
 T60 5.5±0.9 5.4±0.8 5.5±1.0 .901
 ∆ 3.5±0.8 3.5±0.7 3.5±0.9 .933
Free cortisol (nmol/L)* Basal 23.0±13.9 26.1±15.8 24.9±14.4 .619
 T60 77.4±43.1 69.1±45.2 69.1±33.5 .581
 ∆ 54.4±36.2 42.9±36.1 44.2±27.2 .252
*Mean±standard deviation
T60: 60 min after stimulation; ∆: increase from T0 to T60
Table 3. Mean basal and post-stimulation levels of total, free, and salivary cortisol 
among albumin groups
  CTP-A CTP-B CTP-C 
Patients  n: 56 n: 32 n: 22 p**
Age (years)* 60.4± 11.8 66.3±9.8 60.5±11.5 NS
Hematocrit (%)* 39.1±4.3 34.4±6.0 30.7±4.9a .0001
Leukocyte (×103/µL)* 5.09± 1.97 5.66±2.25 6.43±3.22 NS
Platelet (×103/µL)* 115.85±60.10 140.31±9.516 119.50±69.10 NS
Albumin (g/dL)* 3.9±0.4*** 3.1±0.5*** 2.52±0.41*** <.0001
Bilirubin (mg/dL)* 1.05±0.54 1.22±0.61k 4.66±4.88 <.0001
PT (s)*  13.7±2.3 15.4±3.5 17.1±3.4 b <.0001
MELD*  8.5±2.4x 11.2±3.2m 15.9±4.9c <.0001
CBG* (µg/mL) 67.1±38.6 53.4±28.3 42.1±8.4d .006
Creatinine* (µg/dL) 0.75±0.22y 1.01±0.44 0.9±0.4 .002
Ascites  Absent 46 (82.1) 5 (15.6) 1 (4.5) 
n (%) Mild to moderate 10 (17.9) 7 (21.9) 3 (13.6) <.0001
 Severe 0 (0) 20 (62.5) 18 (81.8)
Cryptogenic (%) 11(20) 12(37) 10 (45) -
HBV n (%) 19 (34) 4 (13) 3 (14) -
HCV n (%) 19 (34) 9 (28) 5 (23) -
Other etiologies n (%) 7 (2) 7 (22) 4 (18) -
Peritonitis n (%) 0 4 (13) 6 (27)e .003
Encephalopathy n (%) 0 7 (22)n 13 (59)f <.0001
Diuretic use n (%) 10 (18)g 25 (78) 18 (82)z <.0001
CTP: Child-Turcotte-Pugh; MELD: model for end-stage liver disease; CBG: cortisol-binding globu-
lin; PT: prothrombin time; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NS: non-significant
Within-group comparison was performed after Bonferroni correction. 
*Mean±standard deviation
**p: for comparison within all groups. 
ap<.0001, bp<.0001, cp<.0001, dp=.006, ep<.0001, fp<.0001, gp<.0001 for comparison between A 
and C, respectively.
kp<.0001, mp<.0001, np<.0001 for comparison between B and C, respectively.
xp=.001, yp=.003, zp<.0001 for comparison between A and B, respectively.
***p<.0001 for comparison among A- B, B-C, and A- C.
Table 1. Demographic, clinical, and biochemical parameters of patients 
according to CTP groups
was detected in 20.9% of our stable cirrhotic patients. In a simi-
lar population, Galbois et al. (16) reported a higher rate (33%) 
for AI. AI was detected in 39% of patients who were on the wait-
ing list for liver transplantation (22). We reported AI prevalences 
of 34% and 13% in the groups with high (≥12) and low (<12) 
MELD scores, respectively (p=0.014). Fede et al. (1) reported a 
relatively higher prevalence of 38% for AI. In that trial, 72% of 
enrolled cirrhotic patients were in the CTP-B and CTP-C groups 
with a mean MELD of 17. In our study, only 37.3% of all patients 
had MELD scores of 12 or higher. This heterogeneity of disease 
severity of the patients could explain the different reports of AI 
prevalence rates in several trials.
In serum, more than 90% of cortisol is bound to CBG and al-
bumin (13). Because cirrhotic patients have low CBG levels, 
standard methods for measuring TC levels (including both 
free and protein bound fractions) may overestimate the AI 
rate in this population. In accordance with the literature, in 
our study, CBG levels decreased from the CTP-A to the CTP-C 
groups (16,23). Hamrahian et al. (10) reported high FC levels 
in critically ill hypoproteinemia patients who were diagnosed 
with AI according to basal and post-ACTH levels of TC. These 
data point to the potential misdiagnosis of AI on the basis of 
TC in hypoproteinemia patients and raise questions regarding 
the diagnostic accuracy of TC for such patients. In our study, 
the mean basal TC levels did not differ among albumin groups 
(<2.8 g/dL, 2.8–3.5 g/dL, and >3.5 g/dL), while T60 and ∆ levels 
were significantly lower in the low albumin group (p<0.0001). 
Thevenot et al. (23) reported similar FC levels for patients who 
had hypoalbuminemia (<2.5 g/dL), low CBG levels, and insuf-
ficient response to the ACTH test. We reported similar findings 
with the CTP and MELD groups. In accordance with the sever-
ity of cirrhosis, the trend of post-ACTH TC levels, rather than the 
basal measurements, is insufficient. Differences in CBG levels 
(i.e., decreasing with disease severity) may explain this discrep-
ancy (16,23). Thevenot et al. (23) also defined the associations 
of MELD score, albumin level, and low CBG with insufficient 
cortisol responses to the ACTH test. 
A post-stimulation peak FC level of <33 nmol/L has been 
used to define AI (19,21). Serum FC, estimated with Coolens’ 
formula, was lower than 33 nmol/L in 15.5% of our patients. 
Within the group with the high MELD (≥12) scores, this rate 
reached 24.4%, which was significantly higher than the rate in 
the group with low MELD scores (p=0.044). According to se-
rum FC measurements, Tan et al. (2) reported an AI rate of 12%. 
All these patients had significantly high MELD scores (19±0.8 
vs. 13±0.8) and presented a poor prognosis on follow-up. 
Salivary cortisol has been reported to be correlated with FC 
levels (24). In our study, the basal levels of these two measure-
ments were found to be well correlated (r=0.706, p<0.0001). In 
a recent study reporting a similar correlation, 33% of all cirrhot-
ic patients were diagnosed as having AI with the TC criteria. 
Considering SC, only 9% had a diagnosis of AI that was defined 
as fulfilling at least one of the SC criteria, which include a basal 
level of <1.8 ng/mL, a post-stimulation value of <12.7 ng/mL, 
and an increment of <3 ng/mL. Multivariate analysis indicated 
the independent association of hypoalbuminemia (<25 g/L) 
with the low agreement between SC and TC tests (kappa=0.28) 
for the diagnosis of AI (16).
Considering SC, there is no consensus on the standard thresh-
olds for basal, T60, and ∆ levels in the diagnosis of AI. In the 
literature, the suggested cutoff levels are 1.81 ng/mL for basal 
(25), 3 ng/mL for incremental (26), and 11.7 ng/mL for T60 lev-
els (19). Another reported threshold for the T60 level is 4.9 ng/
mL (27). Due to the conflicting data regarding the definition of 
AI on the basis of SC, it was not possible to present the preva-
lence rate of AI for SC in our study. 
The most important limitation of this study was the lack of 
standard thresholds for SC in the diagnosis of AI. It was pos-
sible to determine the basal reference levels for SC with our 
own kit in the control group. However, due to ethical issues, we 
could not define the post-stimulation reference range for SC in 
healthy controls with our own kit. 
In conclusion, the measurement of TC overestimates the diag-
nosis of AI in cirrhosis. Basal and post-ACTH test levels of TC 
may not reflect the true prevalence of AI in cirrhotic patients, 
particularly among those with high MELD scores. As it corre-
lates well with FC, SC may be a surrogate marker for the di-
agnosis of AI in cirrhosis. For SC to be a valid alternative, more 
studies are needed to determine the optimal basal and post-
stimulation cutoff levels for the diagnosis of AI in cirrhosis.
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n (% ) MELD<12 MELD≥12 p
Free cortisol>33 nmol/L 62 (89.9) 31 (75.6) 0.044
Free cortisol<33 nmol/L 7 (10.1) 10 (24.4) 
MELD: model for end-stage liver disease
Table 4. Adrenal insufficiency for MELD groups according to free cortisol level
 Adrenal  No adrenal 
 insufficiency  insufficiency 
 according to  according to 
n (%) total cortisol total cortisol Kappa 
Free cortisol>33 nmol/L  14 (60.9) 79 (90.8) 
0.331
Free cortisol<33 nmol/L  9 (39.1) 8 (9.2) 
Table 5. Adrenal insufficiency rates according to total cortisol and free 
cortisol levels
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